Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-15
2005-02-15
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S013800, C424S422000, C424S094640, C424S078080, C530S399000, C530S350000, C530S326000
Reexamination Certificate
active
06855687
ABSTRACT:
Disclosed is a method of stimulating cartilage growth, repair or regeneration at a site in a subject in need of such growth, repair or regeneration. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.Also disclosed is a method of stimulating the proliferation and expansion of chrondrocytes in vitro. The method comprises culturing chrondrocytes in the presence of a stimulating amount of an NPAR agonist.
REFERENCES:
patent: 5352664 (1994-10-01), Carney et al.
patent: 5500412 (1996-03-01), Carney et al.
patent: 5876452 (1999-03-01), Athanasiou et al.
patent: 6001352 (1999-12-01), Boyan et al.
patent: WO 8803151 (1988-05-01), None
Kuraray Co Ltd. (Accession No. AAW83414, Dec. 2, 1998).*
Hendel, R.C., et al., “Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion,”Journal of The American Heart Association, 101(2):118-121, (2000).
Aoki, M., et al., “Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets,”Gene Therapy, 7(5):417-427, (2000).
Pecher, P., and Schumacher, B.A., “Angiogenesis is Ischemic Human Myocardium: Clinical Results After 3 Years,”The Annals of Thoracic Surgery, 69(5):1414-1419, (2000).
Kawasuji, M., et al., “Therapeutic Angiogenesis With Intramyocardial Administration of Basic Fibroblast Growth Factor,”The Annals of Thoracic Surgery, 69(4):1155-1161, (2000).
Rosengart, T.K., et al., “Six-Month Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA,”Annals of Surgery, 230(4):466-472, (1991).
Laham, R.J., et al., “Intracorornary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution,”Drug Metabolism and Disposition, 27(7):821-826, (1999).
Sellke, F.W., et al., “Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results,”The Annals of Thoracic Surgery, 65(6):1540-1544, (1998).
Folkman, J., “Angiogenic Therapy of the Human Heart,”Journal of The American Heart Association, 97(7):628-629, (1998).
McKenna, C.J., et al., “Selective ETAReceptor Antagonism Reduces Neointimal Hyperplasia in a Porcine Coronary Stent Model,”Journal of The American Heart Association, 97(25):2551-2556, (1998).
Frimerman, A., et al., “Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model,”Journal of The American Heart Association, 99(5):697-703, (1999).
Voisard, R., et al., “High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis,”Coronary Artery Disease, 8(3/4):189-201, (1997).
Nadir, M., et al., “Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine,”Coronary Artery Disease, 7(11):851-861, (1996).
Munro, E., et al., “Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis,”European Journal of Clinical Investigation, 24(11):766-772, (1994).
Chen, S.J., et al., “Mithramycin Inhibits Myointimal Proliferation After Balloon Injury of the Rat Carotid Artery In Vivo,”Circulation, 90(5):2468-2473, (1994).
Shi, Y., et al., “Downregulation of c-myc Expression by Antisense Oligonucleotides Inhibits Proliferation of Human Smooth Muscle Cells,”Circulation, 88(3):1190-1195, (1993).
Speir, E., and Epstein, S.E., “Inhibition of Smooth Muscle Cell Proliferation by an Antisense Oligodeoxynucleotide Targeting the Messenger RNA Encoding Proliferating Cell Nuclear Antigen,”Circulation, 86(2):538-547, (1992).
Stiernberg, J., et al., “The Role of Thrombin and Thrombin Receptor Activating Peptide (TRAP-508) in Initiation of Tissue Repair,”Thrombosis and Haemostasis, 70(1):158-162, (1995).
Carney, D.H., et al., “Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides,”J. Clin. Invest., 89:1469-1477, (1992).
Carney, D.H., et al., “Role of High-Affinity Thrombin Receptors in Postclotting Cellular Effects of Thrombin,”Seminars in Thrombosis and Hemostasis, 18(1):91-102, (1992).
Stiernberg, J., et al., “Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508,”Wound Repair and Regeneration, 8(3):204-215, (2000).
Glenn, K.C., et al., “Synthetic Peptides Bind to High-Affinity Thrombin Receptors and Modulate Thrombin Mitogenesis,”Peptide Research, 1(2):65-73, (1988).
Sower, L.E., et al., “Thrombin Peptide, TP508, Induces Differential Gene Expression in Fibroblasts through a Nonproteolytic Activation Pathway,”Experimental Cell Research, 247:422-431, (1999).
Carney, D.H., “Postclotting Cellular Effects of Thrombin Mediated by Interaction with High-Affinity Thrombin Receptors,”Thrombin: Structure and Function, Chapter 10, pp. 351-396, (1992).
O'Connor, W.J., et al., “The Use of Growth Factors in Cartilage Repair,”Orthopedic Clinics of North America, 31(3): 399-409 (2000).
Frenkel, S.R., et al., “Transforming Growth Factor Beta Superfamily Members: Role in Cartilage Modeling,”Plastic and Reconstructive Surgery, 105(3): 980-990 (2000).
Sellers, R.S., et al., “Repair of Articular Cartilage Defects One Year After Treatment with Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2),”J. of Bone & Joint Surgery, 82(2): 151-160 (2000).
Sanyal, A., et al., “Initial Evidence for the Involvement of Bone Morphogenetic Protein-2 Early during Periosteal Chondrogenesis,”J. of Orthopaedic Research, 17(6): 926-934 (1999).
Louwerse, R.T., et al., “Use of Recombinant Human Osteogenic Protein-1 for the Repair of Subchondral Defects in Articular Cartilage in Goats,”J. of Biomedical Materials Res., 49(4): 506-516 (2000).
Nixon, A.J., et al., “Enhanced Repair of Extensive Articular Defects by Insulin-Like Growth Factor-I-Laden Fibrin Composites,”J. of Orthopaedic Res., 17:475-487 (1999).
Fujimoto, E., et al., “Beneficial Effect of Basic Fibroblast Growth Factor on the Repair of Full-Thickness Defects in Rabbit Articular Cartilage,”Archives of Orthopaedic and Trauma Surgery, 119(3-4): 139-145 (1999).
Koepp, H.E., et al., “Osteogenic Protein-1(OP-1) Blocks Cartilage Damage Caused by Fibronectin Fragments and Promotes Repair by Enhancing Proteoglycan Synthesis,”Inflammation Res., 48(4): 199-204 (1999).
Hogervorst, T., et al., “The Effect of a TCP-Collagen Implant on the Healing of Articular Cartilage Defects in the Rabbit Knee Joint,”J. of Applied Biomaterials, 3:251-258 (1992).
Reddi, A.H., “Cartilage-Derived Morphogenetic Proteins and Cartilage Morphogenesis,”Microscopy Res. & Technique, 43(2): 131-136 (1998).
Nishida, Y., et al., “Osteogenic proten-1 promotes the synthesis and retention of extracellular matrix within bovine articular cartilage and chondrocyte cultures,”Osteoarthritis and Cartilage, 8: 127-136 (2000).
Crowther, R.S., et al., “Thrombin Peptide TP508 Significantly Accelerates Repair of Fresh Fractures,”Distributed at Texas Mineralized Tissue Society, Austin, Texas. Aug. 1998.
Simmons, D.J., et al., “Acceleration of Rat Femoral Fracture Healing by a Synthetic Thrombin Peptide,”Calcium Metabolism: Comparative Endocrinology. Proc Satellite Meeting, San Francisco, CA. Nov. 30, 1998. (Eds. C. Dacke, J. Danks, G. Flik and C. Gay). BioScientifica Ltd.
Bergmann John
Carney Darrell H.
Crowther Roger S.
Stiernberg Janet
Hamilton Brook Smith & Reynolds P.C.
Robinson Hope A.
The Board of Regents The University of Texas System
Weber Jon
LandOfFree
Stimulation of cartilage growth with agonists of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stimulation of cartilage growth with agonists of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimulation of cartilage growth with agonists of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457034